Rubedo Life Sciences: $40 Million Raised To Develop Therapies Targeting Senescent Cells, Driving Age-Related Diseases
By Amit Chowdhry ● Apr 22, 2024
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells that drive age-related diseases, announced today the closing of a $40 million Series A financing round. This funding round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and additional investors.